These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3661768)

  • 1. Abnormal prolactin response to haloperidol challenge in men with schizophrenia.
    Keks NA; Copolov DL; Singh BS
    Am J Psychiatry; 1987 Oct; 144(10):1335-7. PubMed ID: 3661768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects.
    Copolov DL; Keks NA; Kulkarni J; Singh BS; McKenzie D; McGorry P; Hill C
    Psychoneuroendocrinology; 1990; 15(3):225-31. PubMed ID: 2255750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems.
    Keks NA; Copolov DL; Kulkarni J; Mackie B; Singh BS; McGorry P; Rubin RT; Hassett A; McLaughlin M; van Riel R
    Biol Psychiatry; 1990 Jun; 27(11):1203-15. PubMed ID: 2354227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.
    Davila R; Gonzalez MA; Zumarraga M; Andia I; Guimon J; Silva RR; Friedhoff AJ
    Biol Psychiatry; 1995 Aug; 38(4):267-9. PubMed ID: 8547450
    [No Abstract]   [Full Text] [Related]  

  • 5. Prolactin response to single and multiple doses of haloperidol in schizophrenic patients.
    Ravichandran GK; Lu RB; Shvartsburd A; Misra CH; Ho BT; Kahn M; Smith RC
    Psychiatry Res; 1984 Jan; 11(1):61-9. PubMed ID: 6584932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia.
    Mohr P; Horácek J; Motlová L; Libiger J; Czobor P
    Psychopharmacology (Berl); 1999 Jan; 141(3):322-5. PubMed ID: 10027514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
    Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
    Psychopharmacol Bull; 1992; 28(1):101-7. PubMed ID: 1609034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum prolactin as a correlate of clinical response to haloperidol.
    Van Putten T; Marder SR; Mintz J
    J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidiagnostic evaluation of prolactin response to haloperidol challenge in schizophrenia: maximal blunting in Kraepelinian patients.
    Keks NA; McKenzie DP; Low LH; McGorry PD; Hill C; Kulkarni J; Singh BS; Copolov DL
    Biol Psychiatry; 1992 Sep; 32(5):426-37. PubMed ID: 1486148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia.
    Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S
    Psychopharmacology (Berl); 2002 Jun; 162(1):63-6. PubMed ID: 12107619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haloperidol and droperidol treatment in schizophrenics. Clinical application of the "prolactin-model".
    Langer G; Pühringer W
    Acta Psychiatr Belg; 1980; 80(5):574-83. PubMed ID: 7234451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Submaximal plasma prolactin response to TRH and dopamine activity in man.
    Spoov J
    Pharmacopsychiatry; 1985 Nov; 18(6):330-2. PubMed ID: 3003766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
    Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
    Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of prolactin by dopamine agonists in schizophrenics and controls.
    Rotrosen J; Angrist B; Clark C; Gershon S; Halpers FS; Sachar EJ
    Am J Psychiatry; 1978 Aug; 135(8):949-51. PubMed ID: 665840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic factors in human prolactin regulation: a pituitary model for the study of a neuroendocrine system in man.
    Langer G; Sachar EJ; Nathan RS; Tabrizi MA; Perel JM; Halpern FS
    Psychopharmacology (Berl); 1979 Oct; 65(2):161-4. PubMed ID: 117485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Difference in prolaction response of schizophrenic patients to equivalent doses of haloperidol, remoxipride and sulpiride].
    Liu KL; Lung FW
    Kaohsiung J Med Sci; 1996 Dec; 12(12):685-90. PubMed ID: 9011126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. REM sleep and prolactin in patients with non-affective psychoses.
    Appelberg B; Katila H; Rimón R
    Psychoneuroendocrinology; 2002 Aug; 27(6):661-9. PubMed ID: 12084659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Standard and high doses of haloperidol. Clinical, pharmacokinetic and pharmacodynamic aspects].
    Schilkrut R; Haverbeck C; Duran E; Delgado S; Kohen P; Birkner R; Katz I
    Acta Psiquiatr Psicol Am Lat; 1981; 27(4-5):315-24. PubMed ID: 7348089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variability of prolactin response to intravenous and intramuscular haloperidol in normal adult men.
    Rubin RT; Hays SE
    Psychopharmacology (Berl); 1979 Mar; 61(1):17-24. PubMed ID: 108715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of haloperidol on aldosterone secretion.
    Warner MD; Gillespie H; Pavlou SN; Nader S; Peabody CA
    Psychoneuroendocrinology; 1992 Oct; 17(5):517-21. PubMed ID: 1484918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.